Keywords: Diabetes drugs, GLP-1 based therapies, Risk of pancreatitis, Johns Hopkins, Merck & Co, Januvia, Bristol-Myers, Byetta

Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds

Article | 26 February 2013

Print This

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in